Mga Batayang Estadistika
| CIK | 776008 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rock Creek Pharmaceuticals Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 28, 2016 |
8-K 1 v4495638-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2016 Rock Creek Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other |
|
| August 29, 2016 |
8-K 1 v4479198k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 24, 2016 Rock Creek Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other juri |
|
| August 17, 2016 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2016 Rock Creek Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorporation) (C |
|
| August 10, 2016 |
Rock Creek Pharmaceuticals FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15324 ROCK CREEK P |
|
| July 22, 2016 |
Rock Creek Pharmaceuticals DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| July 11, 2016 |
Rock Creek Pharmaceuticals PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| July 8, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2016 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission File |
|
| July 8, 2016 |
EX-10.1 2 v443884ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 InterIM Note AGREEMENT This Interim Note Agreement (the “Agreement”) dated as of July 7, 2016, is by and among Rock Creek Pharmaceuticals, Inc., a Delaware corporation with offices located at 2040 Whitfield Avenue, Suite 300, Sarasota, Florida 34243 (the “Company”), and the investor signatory hereto (the “Investor”). RECITALS A. The Company and |
|
| July 8, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2016 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission File |
|
| July 8, 2016 |
Exhibit 10.1 InterIM Note AGREEMENT This Interim Note Agreement (the ?Agreement?) dated as of July 7, 2016, is by and among Rock Creek Pharmaceuticals, Inc., a Delaware corporation with offices located at 2040 Whitfield Avenue, Suite 300, Sarasota, Florida 34243 (the ?Company?), and the investor signatory hereto (the ?Investor?). RECITALS A. The Company and the Investor are parties to a Securities |
|
| July 8, 2016 |
Rock Creek Pharmaceuticals FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2016 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission File |
|
| May 16, 2016 |
Rock Creek Pharmaceuticals Provides Clinical Update and Announces 2016 First Quarter Results Exhibit 99.2 Rock Creek Pharmaceuticals Provides Clinical Update and Announces 2016 First Quarter Results SARASOTA, Fla., May 16, 2016 ? Rock Creek Pharmaceuticals, Inc., (OTCQB: RCPI), a clinical-stage drug development company focused on the application of its lead compound to treat acute and chronic inflammatory conditions, today filed its 2016 first quarter report on Form 10-Q with the Securiti |
|
| May 16, 2016 |
May 2016 Rock Creek Pharmaceuticals, Inc. (OTCQB: RCPI) Exhibit 99.1 May 2016 Rock Creek Pharmaceuticals, Inc. (OTCQB: RCPI) Forward Looking Statements Certain statements contained in this presentation constitute forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," |
|
| May 16, 2016 |
8-K 1 v4401628k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2016 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 00 |
|
| May 16, 2016 |
Rock Creek Pharmaceuticals S-8 As filed with the Securities and Exchange Commission on May 16, 2016 Registration No. |
|
| May 16, 2016 |
Rock Creek Pharmaceuticals FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15324 ROCK CREEK |
|
| April 29, 2016 |
424B3 1 v438477424b3.htm 424B3 Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-208016 PROSPECTUS SUPPLEMENT NO. 3 DATED April 29, 2016 (To Prospectus Declared Effective on February 11, 2016) ROCK CREEK PHARMACEUTICALS, INC. 3,626,917 Shares Common Stock This Prospectus Supplement No. 3 supplements information contained in, and should be read in conjunction with, that ce |
|
| April 29, 2016 |
Rock Creek Pharmaceuticals FORM 10-K/A (Annual Report) SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A Amendment No. 1 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-15324 ROCK CREEK PHAR |
|
| April 6, 2016 |
424B3 1 v436368424b3.htm 424B3 Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-208016 PROSPECTUS SUPPLEMENT NO. 2 DATED APRIL 6, 2016 (To Prospectus Declared Effective on February 11, 2016) ROCK CREEK PHARMACEUTICALS, INC. 3,626,917 Shares Common Stock This Prospectus Supplement No. 2 supplements information contained in, and should be read in conjunction with, that cer |
|
| April 5, 2016 |
8-K 1 v4362318k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2016 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporat |
|
| April 5, 2016 |
ROCK CREEK PHARMACEUTICALS, Inc. 2016 OMNIBuS INCENTIVE PLAN Exhibit 10.1 ROCK CREEK PHARMACEUTICALS, Inc. 2016 OMNIBuS INCENTIVE PLAN 1. Purpose, Effective Date and Definitions. (a) Purpose. This Rock Creek Pharmaceuticals, Inc. 2016 Omnibus Incentive Plan has two complementary purposes: (i) to attract, retain, focus and motivate executives and other selected employees, directors, consultants and advisors and (ii) to increase stockholder value. The Plan wi |
|
| April 5, 2016 |
ROCK CREEK PHARMACEUTICALS, INC. 2016 OMNIBUS INCENTIVE PLAN STOCK OPTION AWARD AGREEMENT Exhibit 10.2 ROCK CREEK PHARMACEUTICALS, INC. 2016 OMNIBUS INCENTIVE PLAN STOCK OPTION AWARD AGREEMENT Dear : You have been granted an option (this “Option”) to purchase shares of the common stock of Rock Creek Pharmaceuticals, Inc. (the “Company”) pursuant to the Company’s 2016 Omnibus Incentive Plan (the “Plan”) and this Stock Option Award Agreement (this “Option Agreement”). This Option is gran |
|
| March 31, 2016 |
8-K 1 v4357938k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2016 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) |
|
| March 31, 2016 |
EX-4.1 2 v435793ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THIS WARRANT AND THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXE |
|
| March 31, 2016 |
EX-10.1 3 v435793ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT Between ROCK CREEK PHARMACEUTICALS, INC., as Issuer, And [*] as Investor. Dated: March 30, 2016 This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and effective as of March 30, 2016, between Rock Creek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [*] (“Investor”). WHEREAS, t |
|
| March 28, 2016 |
Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-208016 PROSPECTUS SUPPLEMENT NO. 1 DATED MARCH 28, 2016 (To Prospectus Declared Effective on February 11, 2016) ROCK CREEK PHARMACEUTICALS, INC. 3,626,917 Shares Common Stock This Prospectus Supplement No. 1 supplements information contained in, and should be read in conjunction with, that certain Prospectus of Rock Creek |
|
| March 22, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 v4350298k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2016 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporat |
|
| March 22, 2016 |
Rock Creek Pharmaceuticals Announces 2015 Annual Results and Provides Commentary and Review Exhibit 99.1 Rock Creek Pharmaceuticals Announces 2015 Annual Results and Provides Commentary and Review SARASOTA, Fla., March 22, 2016 ? Rock Creek Pharmaceuticals, Inc., (OTCQB: RCPI), a clinical-stage drug development company focused on the application of its lead compound to treat acute and chronic inflammatory conditions, today filed its annual report on Form 10-K with the Securities and Exch |
|
| March 22, 2016 |
INFORMATION REGARDING SUBSIDIARIES OF THE REGISTRANT EX-21.1 2 v433617ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 INFORMATION REGARDING SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Star Tobacco, Inc. Virginia RCP Development, Inc. Delaware |
|
| March 22, 2016 |
Rock Creek Pharmaceuticals FORM 10-K (Annual Report) 10-K 1 v43361710k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| February 10, 2016 |
Rock Creek Pharmaceuticals ESP ROCK CREEK PHARMACEUTICALS, INC. February 10, 2016 VIA EDGAR Ms. Suzanne Hayes, Assistant Director Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Rock Creek Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-208016 Dear Ms. Hayes: On behalf of Rock Creek Pharmaceuticals, Inc. (the ?Company?) and pursuant to Rule 461 under the Securities Act of 1 |
|
| February 4, 2016 |
Rock Creek Pharmaceuticals ESP ATTORNEYS AT LAW 100 North Tampa Street, Suite 2700 Tampa, FL 33602-5810 P.O. Box 3391 Tampa, FL 33601-3391 813.229.2300 TEL 813.221.4210 FAX www.foley.com WRITER'S DIRECT LINE 813.225.4122 [email protected] EMAIL CLIENT/MATTER NUMBER 107787-0107 February 4, 2016 VIA EDGAR Ms. Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporation Finance U.S. Securities & Exch |
|
| February 4, 2016 |
As filed with the Securities and Exchange Commission on February 4 , 2016 S-1/A 1 v430596s1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on February 4 , 2016 Registration No. 333-208016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or o |
|
| February 4, 2016 |
Exhibit 10.1 AMENDMENT AGREEMENT This Amendment Agreement (the “Agreement”) dated as of February 4, 2016, is by and among Rock Creek Pharmaceuticals, Inc., a Delaware corporation with offices located at 2040 Whitfield Avenue, Suite 300, Sarasota, Florida 34243 (the “Company”), and the party identified as “Buyer” on the signature page hereto (“Buyer”). RECITALS A. The Company and Buyer are parties |
|
| February 4, 2016 |
8-K 1 v4305708k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2016 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpor |
|
| December 15, 2015 |
As filed with the Securities and Exchange Commission on December 15, 2015 S-1/A 1 v426901s1a.htm S-1/A As filed with the Securities and Exchange Commission on December 15, 2015 Registration No. 333-208016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other |
|
| December 15, 2015 |
ATTORNEYS AT LAW 100 North Tampa Street, Suite 2700 Tampa, FL 33602-5810 P.O. Box 3391 Tampa, FL 33601-3391 813.229.2300 TEL 813.221.4210 FAX www.foley.com WRITER'S DIRECT LINE 813.225.4122 [email protected] EMAIL CLIENT/MATTER NUMBER 107787-0107 December 15, 2015 VIA EDGAR Ms. Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporation Finance U.S. Securities & Exc |
|
| November 25, 2015 |
Unassociated Document POWER OF ATTORNEY Know all by these presents, that, for good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the undersigned hereby constitutes and appoints any of William McMahon, Theodore Jenkins, and Curt Creely, acting alone, the undersigned?s true and lawful attorney-in-fact to: 1. |
|
| November 23, 2015 |
8-K 1 v4254328-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorp |
|
| November 13, 2015 |
As filed with the Securities and Exchange Commission on November 13, 2015 As filed with the Securities and Exchange Commission on November 13, 2015 Registration No. |
|
| November 9, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 v42286010q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission F |
|
| November 4, 2015 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 v4237028k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpor |
|
| November 3, 2015 |
Rock Creek Pharmaceuticals PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| October 15, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v4222348k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpor |
|
| October 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction (Commission File Nu |
|
| October 15, 2015 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 14, 2015, is by and among Rock Creek Pharmaceuticals, Inc., a Delaware corporation with offices located at 2040 Whitfield Ave., Ste. 300, Sarasota Florida 34240 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and c |
|
| October 15, 2015 |
Exhibit 99.1 Rock Creek Pharmaceuticals Announces Institutional Financing with Issuance of $20 Million of Convertible Notes Sarasota, Fl., October 15, 2015 /PRNewswire/ Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a clinical stage, drug development company which is focused on the application of its lead compound being developed to treat chronic inflammatory conditions, announced today that th |
|
| October 15, 2015 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of October , 2015, is by and among Rock Creek Pharmaceuticals, Inc., a Delaware corporation with offices located at 2040 Whitfield Ave., Ste. 300, Sarasota Florida 34240 (the ?Company?), and the undersigned buyers (each, a ?Buyer,? and collectively, the ?Buyers?). RECITALS A. In connection wi |
|
| October 15, 2015 |
COMMON STOCK PURCHASE WARRANT ROCK CREEK PHARMACEUTICALS, INC. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 15, 2015 |
[FORM OF SENIOR SECURED CONVERTIBLE NOTE] Exhibit 4.1 [FORM OF SENIOR SECURED CONVERTIBLE NOTE] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) |
|
| October 15, 2015 |
Exhibit 99.1 Rock Creek Pharmaceuticals Announces Successful Completion of Phase I Clinical Trial to Evaluate Oral Formulations of its Lead Compound, Plans to Conduct Proof-of-Concept Trial in Subjects with Mild to Moderate Psoriasis SARASOTA, Fla., October 15, 2015 ? Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a clinical stage drug development company focused on the application of its lead |
|
| September 25, 2015 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commissio |
|
| September 4, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission |
|
| September 4, 2015 |
September 2015 Investor Presentation (NASDAQ:RCPI) Exhibit 99.1 September 2015 Investor Presentation (NASDAQ:RCPI) Forward Looking Statements Certain statements contained in this presentation constitute forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "inte |
|
| August 20, 2015 |
8-K 1 v4187298k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpora |
|
| August 19, 2015 |
EX-99.1 2 v418620ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference Sarasota, Fl., August 19, 2015 /PRNewswire/ Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a clinical stage, drug development company which has focused on the application of its lead compounds to chronic inflammatory conditions, announced |
|
| August 19, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission F |
|
| August 14, 2015 |
Exhibit 99.1 Rock Creek Pharmaceuticals to Present at the 17th Annual Rodman & Renshaw Global Investment Conference Sarasota, Fl., August 14, 2015 /PRNewswire/ Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a clinical stage, drug development company which has focused on the application of its lead compound to chronic inflammatory conditions, announced that the Company will be featured as a pres |
|
| August 14, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission F |
|
| August 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 v41654110q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File N |
|
| August 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission F |
|
| August 10, 2015 |
Exhibit 99.1 Rock Creek Pharmaceuticals Announces Targeting of Dermatological Disease, Updated Clinical and Regulatory Strategy and Second Quarter Results SARASOTA, Fla., August 10, 2015 ? Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a clinical stage, drug development company which has focused on the application of its lead compound to chronic inflammatory conditions, announced today its seco |
|
| July 21, 2015 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 v4158708k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporati |
|
| June 19, 2015 |
Rock Creek Pharmaceuticals Announces Closing of Registered Direct Offering EX-99.1 2 v413652ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rock Creek Pharmaceuticals Announces Closing of Registered Direct Offering Sarasota, FL, June 19, 2015 - Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) (Rock Creek), a drug development company focused on chronic inflammatory disorders, announced that today it has closed its previously announced $3.7 million registered direct offering of 1,644, |
|
| June 19, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission Fil |
|
| June 18, 2015 |
Rock Creek Pharmaceuticals, Inc. 424B5 1 v413432424b5.htm FORM 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-200964 PROSPECTUS SUPPLEMENT (to the Prospectus Dated February 6, 2015) Rock Creek Pharmaceuticals, Inc. This Prospectus Supplement amends and supplements the information in our Prospectus, dated February 6, 2015 (File No. 333-200964). This Prospectus Supplement should be read in conjunction with the Prospect |
|
| June 18, 2015 |
424B5 1 v413394424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-200964 PROSPECTUS SUPPLEMENT (to the Prospectus Dated February 6, 2015) Rock Creek Pharmaceuticals, Inc. 1,644,500 Shares of Common Stock Warrant to Purchase up to 1,233,375 Shares of Common Stock We are offering 1,644,500 shares of our common stock and warrants to purchase up to 1,233,375 shares of our common sto |
|
| June 17, 2015 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 16, 2015, between Rock Creek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co |
|
| June 17, 2015 |
Rock Creek Pharmaceuticals Announces $3.7 Million Registered Direct Offering Exhibit 99.1 Rock Creek Pharmaceuticals Announces $3.7 Million Registered Direct Offering Sarasota, FL, June 17, 2015 - Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) (Rock Creek), a drug development company focused on chronic inflammatory disorders, announced today that it has entered into definitive agreements with institutional investors to raise approximately $3.7 million in a registered dire |
|
| June 17, 2015 |
Exhibit 1.1 PLACEMENT AGENT AGREEMENT June 16, 2015 Maxim Group LLC 405 Lexington Avenue New York, New York 10174 Dear Sirs: 1. INTRODUCTION. Rock Creek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the purchasers, pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and the Securities Purchase Agreement in the for |
|
| June 17, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v4133848k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporati |
|
| June 17, 2015 |
COMMON STOCK PURCHASE WARRANT ROCK CREEK PHARMACEUTICALS, INC. Exhibit 4.1 COMMON STOCK PURCHASE WARRANT ROCK CREEK PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: December 20, 2015 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December 20, 2 |
|
| June 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission Fil |
|
| June 11, 2015 |
Rock Creek Pharmaceuticals Announces Clinical Update Exhibit 99.2 Rock Creek Pharmaceuticals Announces Clinical Update SARASOTA, Fla., June 10, 2015 ? Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today an update on its clinical and regulatory drug development activities. Phase I Trial Update The United Kingdom's Medicines and Healthcare Produc |
|
| June 11, 2015 |
June 2015 Investor Presentation (NASDAQ:RCPI) Exhibit 99.1 June 2015 Investor Presentation (NASDAQ:RCPI) Forward Looking Statements Certain statements contained in this presentation constitute forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," |
|
| June 11, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v4129088k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporati |
|
| June 10, 2015 |
SEPARATION AGREEMENT AND GENERAL RELEASE Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE Rock Creek Pharmaceuticals, Inc., a Delaware corporation (hereinafter "Employer" or ?Company?), and Christopher C. Chapman, MD, his heirs, executors, administrators, successors, and assigns (collectively referred to throughout this Agreement as "Employee"), agree to and intend to be legally bound by the following: 1. Last Day of Employment. a. |
|
| June 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission File |
|
| May 27, 2015 |
IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA Richmond Division Exhibit 10.1 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA Richmond Division IN RE: STAR SCIENTIFIC, INC. ) SECURITIES LITIGATION ) ) Master File No. 3:13cv183 (JAG) ) MEMORANDUM OF UNDERSTANDING REGARDING SETTLEMENT Defendant Rock Creek Pharmaceuticals, Inc. (?Rock Creek?) and Defendant Jonnie Williams (?Williams?) have reached an agreement as to the indemnification iss |
|
| May 27, 2015 |
Rock Creek Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission File |
|
| May 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15324 ROCK CREEK |
|
| May 12, 2015 |
Exhibit 4.2 THIS WARRANT AND THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE SEC |
|
| May 12, 2015 |
Rock Creek Pharmaceuticals FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on F |
|
| May 12, 2015 |
EX-3.1 2 v409875ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ROCK CREEK PHARMACEUTICALS, INC. Rock Creek Pharmaceuticals, Inc. (the “Corporation”), organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. The original name of the Co |
|
| May 12, 2015 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT Between ROCK CREEK PHARMACEUTICALS, INC., as Issuer, And FEEHAN PARTNERS, LP, as Investor. Dated: May 8, 2015 This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is entered into and effective as of May 8, 2015, between Rock Creek Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Feehan Partners, LP (?Investor?). WHEREAS, Investor has pr |
|
| May 11, 2015 |
Exhibit 4.3 AMENDMENT TO THE THIRD AMENDED AND RESTATED ROCK CREEK PHARMACEUTICALS, INC. 2008 INCENTIVE AWARD PLAN THIS AMENDMENT TO THE THIRD AMENDED AND RESTATED ROCK CREEK PHARMACEUTICALS, INC. 2008 INCENTIVE AWARD PLAN (this ?Amendment?) is made and adopted as of April 10, 2015 by Rock Creek Pharmaceuticals, Inc. (f/k/a Star Scientific, Inc.), a Delaware corporation (the ?Company?). Capitalize |
|
| May 11, 2015 |
Rock Creek Pharmaceuticals FORM S-8 As filed with the Securities and Exchange Commission on May 11, 2015 Registration No. |
|
| April 20, 2015 |
UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA ALEXANDRIA DIVISION Exhibit 99.1 UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA ALEXANDRIA DIVISION In re Star Scientific, Inc. ) Derivative Litigation ) Lead Case No. 1:13-CV-550-AJT-JFA ) This Document Relates to: ) ) ALL ACTIONS ) ) IN THE CIRCUIT COURT OF THE CITY OF RICHMOND John Marshall Courts Building In re Star Scientific, Inc. Virginia Circuit ) Court Derivative Litigation ) Lead Case No. |
|
| April 20, 2015 |
Rock Creek Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission Fi |
|
| April 20, 2015 |
UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA ALEXANDRIA DIVISION Exhibit 99.2 EXECUTION COPY UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA ALEXANDRIA DIVISION In re Star Scientific, Inc. ) Derivative Litigation ) Lead Case No. 1:13-CV-550-AJT-JFA ) This Document Relates to: ) ) ALL ACTIONS ) ) IN THE CIRCUIT COURT OF THE CITY OF RICHMOND John Marshall Courts Building In re Star Scientific, Inc. Virginia Circuit ) Court Derivative Litigation |
|
| April 13, 2015 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ROCK CREEK PHARMACEUTICALS, INC. Rock Creek Pharmaceuticals, Inc. (the ?Corporation?), organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), hereby certifies as follows: 1. The original name of the Corporation was Eye Technology, Inc. and |
|
| April 13, 2015 |
Exhibit 10.1 AMENDMENT TO THE THIRD AMENDED AND RESTATED ROCK CREEK PHARMACEUTICALS, INC. 2008 INCENTIVE AWARD PLAN THIS AMENDMENT TO THE THIRD AMENDED AND RESTATED ROCK CREEK PHARMACEUTICALS, INC. 2008 INCENTIVE AWARD PLAN (this ?Amendment?) is made and adopted as of April 10, 2015 by Rock Creek Pharmaceuticals, Inc. (f/k/a Star Scientific, Inc.), a Delaware corporation (the ?Company?). Capitaliz |
|
| April 13, 2015 |
Rock Creek Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2015 Rock Creek Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorporation) (Co |
|
| April 8, 2015 |
8-K 1 v4068818-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporat |
|
| April 8, 2015 |
Exhibit 17.1 Dear Board Members: It is with regret that I hereby resign from the Rock Creek Pharmaceutical, Inc. Board of Directors, effective April 2, 2015. Management?s decision to begin dosing healthy volunteers with the study drug anatabine in a U.K. clinical trial approved by the MHRA, without first clearing the FDA?s Full Clinical Hold Order ? an order directing the company not to initiate t |
|
| March 23, 2015 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 v4053218k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporat |
|
| March 13, 2015 |
Rock Creek Pharmaceuticals ESP ROCK CREEK PHARMACEUTICALS, INC. March 13, 2015 VIA EDGAR Mr. Jeffrey Riedler, Assistant Director Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Rock Creek Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-202131 Dear Mr. Riedler: On behalf of Rock Creek Pharmaceuticals, Inc. (the ?Company?) and pursuant to Rule 461 under the Securities Act of |
|
| March 13, 2015 |
Rock Creek Pharmaceuticals DEF 14A DEF 14A 1 v403573def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| March 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K 10-K 1 v40358710k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| March 12, 2015 |
INFORMATION REGARDING SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 INFORMATION REGARDING SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Star Tobacco, Inc. Virginia RCP Development, Inc. Delaware |
|
| March 2, 2015 |
RCPI / Rock Creek Pharmaceuticals, Inc. CORRESP - - March 2, 2015 Via EDGAR and email Mr. Jeffrey P. Riedler Assistant Director United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 Washington, D.C. 20549 Re: Rock Creek Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed on February 23, 2015 File No. 000-15324 Dear Mr. Riedler: Rock Creek Pharmaceuticals, Inc. (the “Company”), in respons |
|
| March 2, 2015 |
RCPI / Rock Creek Pharmaceuticals, Inc. CORRESP - - March 2, 2015 ATTORNEYS AT LAW 100 North Tampa Street, Suite 2700 Tampa, FL 33602-5810 P. |
|
| February 25, 2015 |
8-K 1 v4027088k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo |
|
| February 23, 2015 |
RCPI / Rock Creek Pharmaceuticals, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| February 17, 2015 |
RCPI / Rock Creek Pharmaceuticals, Inc. S-3 - - FORM S-3 S-3 1 v401798s3.htm FORM S-3 As filed with the Securities and Exchange Commission on February 17, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpora |
|
| February 4, 2015 |
RCPI / Rock Creek Pharmaceuticals, Inc. S-3/A - - S-3/A S-3/A 1 v397997s3a.htm S-3/A As filed with the Securities and Exchange Commission on February 4, 2015 Registration No. 333-200964 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other j |
|
| January 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission |
|
| January 30, 2015 |
EX-99.1 2 v399911ex99-1.htm EXHIBIT 99.1 Rock Creek Pharmaceuticals Receives Clinical Trial Application Approval - Phase I Trial begins in the United Kingdom - Sarasota, FL, January 30, 2015 - Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disorders, announced today that the United Kingdom’s Medicines Healthcare Products Regulatory Agenc |
|
| January 30, 2015 |
Exhibit 10.1 SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT Between ROCK CREEK PHARMACEUTICALS, INC., as Issuer, And The Investors Set Forth on Schedule I hereto Dated: January 28, 2015 This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into and effective as of January 28, 2015, between Rock Creek Pharmaceuticals, Inc., a Delaware corporation (the “Comp |
|
| January 30, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 v3999118k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpor |
|
| January 30, 2015 |
Exhibit 4.1 BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY THIS WARRANT AND THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE SEC |
|
| January 16, 2015 |
8-K 1 v3988258-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo |
|
| January 12, 2015 |
January 12, 2015 Biotech Showcase 2015 EXHIBIT 99.1 January 12, 2015 Biotech Showcase 2015 Forward Looking Statements Certain statements that will be made during this presentation constitute forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "inte |
|
| January 12, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2015 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission |
|
| December 15, 2014 |
Exhibit 4.1 CERTIFICATE OF AMENDMENT TO THE TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ROCK CREEK PHARMACEUTICALS, INC. Rock Creek Pharmaceuticals, Inc. (the “Corporation”), organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. The original name of the Corporation was Eye Technology, Inc. and |
|
| December 15, 2014 |
Exhibit 4.3 AMENDMENT TO THE THIRD AMENDED AND RESTATED ROCK CREEK PHARMACEUTICALS, INC. 2008 INCENTIVE AWARD PLAN THIS AMENDMENT TO THE THIRD AMENDED AND RESTATED ROCK CREEK PHARMACEUTICALS, INC. 2008 INCENTIVE AWARD PLAN (this “Amendment”) is made and adopted as of November 21, 2014 by Rock Creek Pharmaceuticals, Inc. (f/k/a Star Scientific, Inc.), a Delaware corporation (the “Company”). Capital |
|
| December 15, 2014 |
RCPI / Rock Creek Pharmaceuticals, Inc. S-3 - - S-3 As filed with the Securities and Exchange Commission on December 15, 2014 Registration No. |
|
| December 15, 2014 |
RCPI / Rock Creek Pharmaceuticals, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on December 15, 2014 Registration No. |
|
| December 15, 2014 |
Exhibit 1.2 EXECUTION VERSION ROCK CREEK PHARMACEUTICALS, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales Agreement December 15, 2014 MLV & Co. LLC 1251 Avenue of the Americas 41st Floor New York, New York 10020 Ladies and Gentlemen: Rock Creek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV |
|
| December 15, 2014 |
Exhibit 12.1 Rock Creek Pharmaceuticals, Inc. Computation of Ratio of Earnings to Fixed Charges ($ thousands) Year Ended December 31, Nine Months ended September 30, 2014 2009 2010 2011 2012 2013 Computation of earnings: Net loss from continuing operations before provision for income taxes $ (17,369 ) $ (25,629 ) $ (35,893 ) $ (18,100 ) $ (33,229 ) $ (27,971 ) Fixed Charges as calculated below 474 |
|
| December 11, 2014 |
Financial Statements and Exhibits, Other Events 8-K 1 v3963478k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2014 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo |
|
| December 11, 2014 |
Rock Creek Pharmaceuticals Announces Listing Extension on NASDAQ EX-99.1 2 v396347ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rock Creek Pharmaceuticals Announces Listing Extension on NASDAQ SARASOTA, FL., December 11, 2014 – Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it received notification from the Nasdaq Stock Market, Inc. granting a six-month e |
|
| November 25, 2014 |
EX-3.1 2 v395273ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ROCK CREEK PHARMACEUTICALS, INC. Rock Creek Pharmaceuticals, Inc. (the “Corporation”), organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. The original name of the Co |
|
| November 25, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 21, 2014 Rock Creek Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorporation) |
|
| November 25, 2014 |
Exhibit 10.1 AMENDMENT TO THE THIRD AMENDED AND RESTATED ROCK CREEK PHARMACEUTICALS, INC. 2008 INCENTIVE AWARD PLAN THIS AMENDMENT TO THE THIRD AMENDED AND RESTATED ROCK CREEK PHARMACEUTICALS, INC. 2008 INCENTIVE AWARD PLAN (this “Amendment”) is made and adopted as of November 21, 2014 by Rock Creek Pharmaceuticals, Inc. (f/k/a Star Scientific, Inc.), a Delaware corporation (the “Company”). Capita |
|
| November 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15324 ROCK CR |
|
| November 3, 2014 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2014 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission |
|
| October 17, 2014 |
RCPI / Rock Creek Pharmaceuticals, Inc. DEF 14A - - DEF 14A Submission Proof - v390864 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 3, 2014 |
RCPI / Rock Creek Pharmaceuticals, Inc. PRE 14A - - PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| September 24, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2014 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commissio |
|
| September 24, 2014 |
BioPharm America 2014 September 24, 2014 Exhibit 99.1 BioPharm America 2014 September 24, 2014 Forward Looking Statements Certain statements that will be made during this presentation constitute forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "in |
|
| August 18, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the quarterly period ended June 30, 2014 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-1 |
|
| August 18, 2014 |
Exhibit 10.3 Execution Copy AGREEMENT This Agreement is entered into as of the 20th day of June, 2014, by and between Rock Creek Pharmaceuticals, Inc. (f/k/a Star Scientific, Inc.), with its principal place of business at 2040 Whitfield Avenue, Suite 300, Sarasota, Florida 34243 (the ?Company?), and David M. Dean, an individual residing at 35 Hunting Ridge Road, Manakin-Sabot, Virginia 23103 (?Emp |
|
| August 11, 2014 |
AMENDMENT NO. 1 TO LOAN AGREEMENT Exhibit 10.6 AMENDMENT NO. 1 TO LOAN AGREEMENT This Amendment No. 1 to Loan Agreement (?Amendment?) is made effective as of August 8, 2014 (the ?Effective Date?), by and between Rock Creek Pharmaceuticals, Inc. (f/k/a Star Scientific, Inc.) (the ?Company?) and John Joseph McKeon (?Lender?). Capitalized terms not otherwise defined herein shall have the meanings assigned to such terms in the Agreeme |
|
| August 11, 2014 |
Exhibit 10.4 LEASE AGREEMENT THIS LEASE, effective as of the 1st day of March 2014, by and between The Roskamp Institute Inc., or its successors or assigns, a Florida nonprofit corporation (?Landlord?) and Star Scientific, Inc. (?Tenant?). WITNESSETH: 1. LEASE OF PREMISES. Upon and subject to the terms and conditions provided herein, Landlord leases to Tenant and Tenant leases from Landlord, certa |
|
| August 11, 2014 |
Exhibit 10.5 SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT Between ROCK CREEK PHARMACEUTICALS, INC., as Issuer, And , as Investor. Dated: August 8, 2014 This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is entered into and effective as of August 8, 2014, between Rock Creek Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and (?Investor?). WHEREAS, |
|
| August 11, 2014 |
EX-10.7 5 v385841ex10-7.htm EXHIBIT 10.7 Exhibit 10.7 LOAN AGREEMENT US $1,750,000 August 8, 2014 This Loan Agreement (“Agreement”) is entered into as of the date set forth above between Rock Creek Pharmaceuticals, Inc., a Delaware corporation with a place of business at 2040 Whitfield Avenue, Ste. 300, Sarasota, FL 34243 (the “Company”), and Feehan Partners, LP, a California limited partnership w |
|
| August 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the quarterly period ended June 30, 2014 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15324 ROCK CREEK PH |
|
| August 6, 2014 |
8-K 1 v3859598k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2014 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporat |
|
| August 6, 2014 |
Rock Creek Pharmaceuticals Expands The Board with the Appointment of Two Independent Directors Exhibit 99.1 Rock Creek Pharmaceuticals Expands The Board with the Appointment of Two Independent Directors Sarasota, Fl., August 06, 2014 /PRNewswire/ Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has made two key independent appointments to the Company’s Board of Directors with the recent election of Ms. Lee M. Canaan, CFA and Mr. Edward J. McDonnell, MPH. as new di |
|
| July 16, 2014 |
Rock Creek Pharmaceuticals, Inc. 14,867,940 Shares of Common Stock 424B3 1 v383967424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-196540 Prospectus Rock Creek Pharmaceuticals, Inc. 14,867,940 Shares of Common Stock This prospectus covers the offer and sale by the selling stockholders identified in this prospectus of up to 14,867,940 shares of common stock, $0.0001 par value per share, of Rock Creek Pharmaceuticals, Inc. (f/k/a Star Scientifi |
|
| July 11, 2014 |
RCPI / Rock Creek Pharmaceuticals, Inc. CORRESP - - ROCK CREEK PHARMACEUTICALS, INC. July 11, 2014 VIA EDGAR Mr. Jeffrey Riedler, Assistant Director Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Rock Creek Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-196540 Dear Mr. Riedler: On behalf of Rock Creek Pharmaceuticals, Inc. (the “Company”) and pursuant to Rule 461 under the Securities Act of 1 |
|
| July 11, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2014 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission Fil |
|
| July 11, 2014 |
Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application Exhibit 99.1 Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application Sarasota, FL. July 11, 2014 /PRNewswire/ Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), an emerging biotechnology company, today announced that the Food and Drug Administration (“FDA”), has notified the Company that the agency will provide comments on RCP’s Investigational New Drug (“IND”) applicatio |
|
| July 1, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2014 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission File |
|
| July 1, 2014 |
v382825ex99-1 - Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing Exhibit 99.1 |
|
| June 26, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2014 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission Fil |
|
| June 23, 2014 |
ATTORNEYS AT LAW 100 North Tampa Street, Suite 2700 Tampa, FL 33602-5810 P.O. Box 3391 Tampa, FL 33601-3391 813.229.2300 TEL 813.221.4210 FAX www.foley.com WRITER’S DIRECT LINE 813.225.4122 [email protected] EMAIL CLIENT/MATTER NUMBER 107787-0104 June 23, 2014 VIA EDGAR Mr. Jeffrey P. Riedler Assistant Director Securities and Exchange Commission 100 F. Street N.E. Washington, D.C. 20549 Re: Rock C |
|
| June 23, 2014 |
S-3/A 1 v381701s3a.htm FORM S-3/A As filed with the Securities and Exchange Commission on June 23, 2014 Registration No. 333-196540 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 52-1402131 (Sta |
|
| June 5, 2014 |
As filed with the Securities and Exchange Commission on June 5, 2014 Registration No. |
|
| June 4, 2014 |
Exhibit 4.1 |
|
| June 4, 2014 |
BY-LAWS ROCK CREEK PHARMACEUTICALS, INC. (as amended and restated on June 4, 2014) ARTICLE I. EX-3.2 3 v380587ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 BY-LAWS OF ROCK CREEK PHARMACEUTICALS, INC. (as amended and restated on June 4, 2014) ARTICLE I. OFFICES SECTION 1. REGISTERED OFFICE. The registered office of Rock Creek Pharmaceuticals, Inc. f/k/a Star Scientific, Inc. (hereinafter called the “Corporation”) in the State of Delaware is located at 2711 Centerville Road, in the City of Wilmington, C |
|
| June 4, 2014 |
8-K 1 v3805878k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2014 ROCK CREEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporatio |
|
| June 4, 2014 |
Exhibit 3.1 TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF STAR SCIENTIFIC, INC. (formerly Eye Technology, Inc.) The undersigned, a natural person, for the purpose of amending and restating, the Certificate of Incorporation of Star Scientific, Inc., as originally filed on June 24, 1985, and as amended and restated on June 22, 1988, May 19, 1992, September 24, 2001, December 14, 2007, D |
|
| June 2, 2014 |
Star Scientific Announces Corporate Name Change to Rock Creek Pharmaceuticals Exhibit 99.1 Star Scientific Announces Corporate Name Change to Rock Creek Pharmaceuticals GLEN ALLEN, Va. June 02, 2014 /PRNewswire/ - Star Scientific, Inc. (NASDAQ: STSI) announced that the Company will formally change its corporate name to Rock Creek Pharmaceuticals, Inc. effective June 4, 2014, with a new ticker symbol of “RCPI” to begin trading on the NASDAQ effective June 4, 2014. A new corp |
|
| June 2, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v3804198k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2014 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-1532 |
|
| May 23, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2014 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission File Number) 52 |
|
| May 23, 2014 |
SEPARATION AND CONSULTING AGREEMENT Exhibit 10.1 Execution Copy SEPARATION AND CONSULTING AGREEMENT This Separation and Consulting Agreement (“Agreement”) is entered as of May 19, 2014 (“Separation Date”), by and between Star Scientific, Inc. (“Company”), a Delaware corporation with its principal place of business at 2040 Whitfield Ave., Sarasota, Florida 34243, and Paul L. Perito, Esquire (“Executive”), of 6219 Kennedy Drive, Chase |
|
| May 12, 2014 |
Exhibit 10.4 Execution Version SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT Between STAR SCIENTIFIC, INC., as Issuer, And The Investors Set Forth on Schedule I hereto March 12, 2014 This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is entered into and effective as of March 12, 2014, between Star Scientific, Inc., a Delaware corporation (the ?Company?), and the |
|
| May 12, 2014 |
EX-4.1 2 v377699ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THIS PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF APPLICABLE STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE AC |
|
| May 12, 2014 |
Exhibit 10.6 Execution Version SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT Between STAR SCIENTIFIC, INC., as Issuer, And The Investors Set Forth on Schedule I hereto March 12, 2014 This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is entered into and effective as of March 12, 2014, between Star Scientific, Inc., a Delaware corporation (the ?Company?), and the |
|
| May 12, 2014 |
EX-10.5 9 v377699ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 Execution Version SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT Between STAR SCIENTIFIC, INC., as Issuer, And The Investors Set Forth on Schedule I hereto March 12, 2014 This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into and effective as of March 12, 2014, between Star Scientific, Inc., a Delaw |
|
| May 12, 2014 |
EX-4.2 3 v377699ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 THIS WARRANT AND THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXE |
|
| May 12, 2014 |
Exhibit 4.3 THIS WARRANT AND THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE SEC |
|
| May 12, 2014 |
EX-10.3 7 v377699ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 Execution Version SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT Between STAR SCIENTIFIC, INC., as Issuer, And The Investors Set Forth on Schedule I hereto March 12, 2014 This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into and effective as of March 12, 2014, between Star Scientific, Inc., a Delaw |
|
| May 12, 2014 |
Exhibit 10.1 LOAN AGREEMENT US $5,800,000 March 12, 2014 This Loan Agreement (?Agreement?) is entered into as of the date set forth above between Star Scientific, Inc., a Delaware corporation with a place of business at 4470 Cox Road, Suite 110, Glen Allen, Virginia 23060 (the ?Company?), and John Joseph McKeon, an individual with an address at 15A Golf Village, Key Largo, FL 33037 (in his persona |
|
| May 12, 2014 |
Exhibit 10.7 Execution Version SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT Between STAR SCIENTIFIC, INC., as Issuer, And The Investors Set Forth on Schedule I hereto March 12, 2014 This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is entered into and effective as of March 12, 2014, between Star Scientific, Inc., a Delaware corporation (the ?Company?), and the |
|
| May 12, 2014 |
Exhibit 10.2 Execution Version SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT Between STAR SCIENTIFIC, INC., as Issuer, And The Investors Set Forth on Schedule I hereto March 12, 2014 This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is entered into and effective as of March 12, 2014, between Star Scientific, Inc., a Delaware corporation (the ?Company?), and the |
|
| May 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15324 STAR SCIENT |
|
| May 2, 2014 |
AGREEMENT This Agreement is entered into as of the 30th day of April, 2014, by and among Star Scientific, Inc. |
|
| May 2, 2014 |
8-K 1 v3769708k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2014 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-15324 ( |
|
| April 30, 2014 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A Amendment No. 1 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A Amendment No. 1 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-15324 STAR SCIENTIFIC |
|
| April 10, 2014 |
EX-99.2 Exhibit 2 TRADEWINDS INVESTMENT PARTNERS, LLC Three Harbor Drive Suite 213 Sausalito, CA 94965 POWER OF ATTORNEY I represent Tradewinds Investment Partners, LLC (the “Company”) and hereby appoint Jay B. Gould and Michael Wu of Pillsbury Winthrop Shaw Pittman LLP, to act on behalf of the Company, its affiliates and persons directly or indirectly controlling, controlled by or under common co |
|
| April 10, 2014 |
TRADEWINDS CAPITAL, L.P. Three Harbor Drive Suite 213 Sausalito, CA 94965 POWER OF ATTORNEY EX-99.1 Exhibit 1 TRADEWINDS CAPITAL, L.P. Three Harbor Drive Suite 213 Sausalito, CA 94965 POWER OF ATTORNEY I represent Tradewinds Capital, L.P. (the “Partnership”) and hereby appoint Jay B. Gould of Pillsbury Winthrop Shaw Pittman LLP to act on behalf of the Partnership, its affiliates and persons directly or indirectly controlling, controlled by or under common control with the Partnership, fo |
|
| April 10, 2014 |
RCPI / Rock Creek Pharmaceuticals, Inc. / Peters Scott - SC 13D/A Activist Investment SC 13D/A Draft 4/4/14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 10, 2014 |
Robert W. Scannell Three Harbor Drive Suite 213 Sausalito, CA 94965 POWER OF ATTORNEY EX-99.7 Exhibit 7 Robert W. Scannell Three Harbor Drive Suite 213 Sausalito, CA 94965 POWER OF ATTORNEY I hereby appoint Jay B. Gould of Pillsbury Winthrop Shaw Pittman LLP to act on my behalf for the purpose of signing and filing all documents with the U.S. Securities and Exchange Commission. I have caused this Power of Attorney to be executed this 26th day of March, 2014. /s/ Robert W. Scannell |
|
| April 10, 2014 |
EX-99.3 Exhibit 3 TRADEWINDS INVESTMENT MANAGEMENT, L.P. Three Harbor Drive Suite 213 Sausalito, CA 94965 POWER OF ATTORNEY I represent Tradewinds Investment Management, L.P. (the “Company”) and hereby appoint Jay B. Gould and Michael Wu of Pillsbury Winthrop Shaw Pittman LLP, to act on behalf of the Company, its affiliates and persons directly or indirectly controlling, controlled by or under com |
|
| April 7, 2014 |
Material Modification to Rights of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): 4/3/14 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 28, 2014 |
S-8 1 v372936s8.htm S-8 As filed with the Securities and Exchange Commission on March 28, 2014 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Star Scientific, Inc. (Exact name of Registrant as specified in its charter) Delaware 52-1402131 (State or other jurisdiction of incorporation or organization) |
|
| March 17, 2014 |
EXECUTIVE EMPLOYMENT AGREEMENT EXHIBIT 10.85 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement") is entered into as of December 27, 2013, by and between STAR SCIENTIFIC, INC., a Delaware corporation and its successors (the "Company"), and Michael J. Mullan ("Executive"). Recitals A. The Company is engaged in the research, development, manufacturing and commercialization of nutraceutical dietary |
|
| March 17, 2014 |
AMENDMENT TO STOCK OPTION AWARD AGREEMENT DATED December 26, 2013 EXHIBIT 10.89 [number] Options AMENDMENT TO STOCK OPTION AWARD AGREEMENT DATED December 26, 2013 Reference is made to a certain Stock Option Award Agreement (hereinafter the “Stock Option Agreement”) dated , 20, between Star Scientific, Inc. (the “Company”) and (the “Director”). As authorized pursuant to Section 5.1(b) of the Star Scientific, Inc. 2008 Incentive Award Plan, as amended from time to |
|
| March 17, 2014 |
THIRD AMENDED AND RESTATED STAR SCIENTIFIC, INC. 2008 INCENTIVE AWARD PLAN ARTICLE 1. EX-10.5 2 v371226ex10-5.htm EXHIBIT 10.5 EXHIBIT 10.5 THIRD AMENDED AND RESTATED STAR SCIENTIFIC, INC. 2008 INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Star Scientific, Inc. 2008 Incentive Award Plan (the “Plan”) is to promote the success and enhance the value of Star Scientific, Inc. (the “Company”) by linking the personal interests of the members of the Board, Employees, and Consu |
|
| March 17, 2014 |
EX-10.87 5 v371226ex10-87.htm EXHIBIT 10.87 EXHIBIT 10.87 SECOND AMENDMENT TO THE EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN STAR SCIENTIFIC, INC. AND JONNIE R. WILLIAMS, SR. This Second Amendment (“Second Amendment”) to that certain Executive Employment Agreement between Star Scientific, Inc., a Delaware corporation (the “Company”) and Jonnie R. Williams, Sr. (“Employee”) dated as of March 14, 2011 ( |
|
| March 17, 2014 |
EXHIBIT 10.88 SECOND AMENDMENT TO THE THIRD AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN STAR SCIENTIFIC, INC. AND PAUL L. PERITO This Amendment (“Amendment”) to that certain Third Amended and Restated Executive Employment Agreement between Star Scientific, Inc., a Delaware corporation (the “Company”) and Paul L. Perito (“Executive”) dated as of March 14, 2011 (the “Executive Employ |
|
| March 17, 2014 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K 10-K 1 v37122610k.htm FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-15324 S |
|
| March 17, 2014 |
INFORMATION REGARDING SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 INFORMATION REGARDING SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Star Tobacco, Inc. Virginia Rock Creek Pharmaceuticals, Inc. Delaware |
|
| March 17, 2014 |
EXECUTIVE EMPLOYMENT AGREEMENT EXHIBIT 10.86 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement") is entered into as of December 27, 2013, by and between STAR SCIENTIFIC, INC., a Delaware corporation and its successors (the "Company"), and Christopher C. Chapman ("Executive"). Recitals A. The Company is engaged in the research, development, manufacturing and commercialization of nutraceutical di |
|
| February 18, 2014 |
RCPI / Rock Creek Pharmaceuticals, Inc. / McKeon John Joseph - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) STAR SCIENTIFIC, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 85517P101 (CUSIP Number) December 31, 2013 (Date of Event which Requires filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 14, 2014 |
8-K 1 v3684648k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 10, 2014 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction |
|
| January 10, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2014 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction (Commission (IRS Employer of i |
|
| January 10, 2014 |
Star Scientific Announces Details for January 15 Conference Call Exhibit 99.1 Star Scientific Announces Details for January 15 Conference Call GLEN ALLEN, Va., Jan. 10, 2014 /PRNewswire/ - Star Scientific, Inc., (NASDAQ: STSI) announced today that its conference call presentation announced on January 2, 2014, will be held at 4 p.m. ET on Wednesday, January 15, 2014. The conference call can be accessed on Star Scientific’s website by going to www.starscientific. |
|
| January 2, 2014 |
Star Scientific Receives a Warning Letter From the FDA Regarding Consumer Exhibit 99.3 Star Scientific Receives a Warning Letter From the FDA Regarding Consumer Products GLEN ALLEN, Va., Dec. 31, 2013 /PRNewswire/-Star Scientific, Inc. (NASDAQ:STSI) announced the receipt on December 24, 2013, of a warning letter from the U.S. Food and Drug Administration (FDA) regarding two consumer products, Anatabloc® and CigRx®, which are marketed by the Company. The letter requires |
|
| January 2, 2014 |
8-K 1 v3644248k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 26, 2013 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction (Comm |
|
| January 2, 2014 |
v364424ex3-1 - Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing |
|
| January 2, 2014 |
Star Scientific, Inc. Arranges a $15 Million Credit Facility Exhibit 99.2 Star Scientific, Inc. Arranges a $15 Million Credit Facility GLEN ALLEN, Va., Dec. 31, 2013/PRNewswire/ - Star Scientific, Inc., (NASDAQ: STSI) announced that today it has entered into a Letter of Intent for a $15 million Credit Facility with Jonnie R. Williams, Sr. the Company’s founder and its former CEO. The Credit Facility extends through April 15, 2015. Under the Credit Facility, |
|
| January 2, 2014 |
Excerpt from Form 8-K filed with the SEC on November 8, 2013 Exhibit 99.1 Excerpt from Form 8-K filed with the SEC on November 8, 2013 Arrangements with Drs. Mullan and Chapman As part of the corporate transition matters, we intend to enter into compensation arrangements with Drs. Chapman and Mullan. The terms of these arrangements (which have been set forth in executed terms sheets between the Company and Drs. Chapman and Mullan, each dated as of November |
|
| November 27, 2013 |
CORRESP 1 filename1.htm November 27, 2013 VIA EDGAR AND BY COURIER Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington DC 20549 Re: Star Scientific, Inc. Form 10-K for the fiscal year ended December 31, 2012 Filed March 18, 2013, File No. 001-15324 Comment Letter Dated July 11, 2013 Follow up Com |
|
| November 18, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| November 12, 2013 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the quarterly period ended September 30, 2013 Or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15324 STAR SCIENTIFIC, INC. |
|
| November 8, 2013 |
8-K 1 v3596178k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2013 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction ( |
|
| November 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| October 23, 2013 |
October 23, 2013 VIA EDGAR AND BY COURIER Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington DC 20549 Re: Star Scientific, Inc. Form 10-K for the fiscal year ended December 31, 2012 Filed March 18, 2013, File No. 001-15324 Comment Letter Dated July 11, 2013 Follow up Comment Letter Dated Septemb |
|
| October 7, 2013 |
CORRESP 1 filename1.htm October 7, 2013 VIA EDGAR Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington DC 20549 Re: Star Scientific, Inc. Form 10-K for the fiscal year ended December 31, 2012 Filed March 18, 2013, File No. 001-15324 Comment Letter Dated July 11, 2013 Follow up Comment Letter Dated |
|
| October 3, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): 10/2/13 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 29, 2013 |
August 29, 2013 VIA EDGAR AND BY COURIER Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington DC 20549 Re: Star Scientific, Inc. Form 10-K for the fiscal year ended December 31, 2012 Filed March 18, 2013, File No. 001-15324 Comment Letter Dated July 11, 2013 Follow up Comment Letter Dated August 2 |
|
| August 9, 2013 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the quarterly period ended June 30, 2013 Or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15324 STAR SCIENTIFIC, INC. |
|
| July 25, 2013 |
CORRESP 1 filename1.htm July 25, 2013 VIA EDGAR AND COURIER Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington DC 20549 Re: Star Scientific, Inc. Form 10-K for the fiscal year ended December 31, 2012 Filed March 18, 2013, File No. 001-15324 Comment Letter Dated July 11, 2013 Dear Mr. Rosenberg: |
|
| May 10, 2013 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the quarterly period ended March 31, 2013 Or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15324 STAR SCIENTIFIC, INC. |
|
| April 30, 2013 |
SECOND AMENDED AND RESTATED STAR SCIENTIFIC, INC. 2008 INCENTIVE AWARD PLAN ARTICLE 1. Exhibit 10.5 SECOND AMENDED AND RESTATED STAR SCIENTIFIC, INC. 2008 INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Star Scientific, Inc. 2008 Incentive Award Plan (the “Plan”) is to promote the success and enhance the value of Star Scientific, Inc. (the “Company”) by linking the personal interests of the members of the Board, Employees, and Consultants to those of the Company’s stockho |
|
| April 30, 2013 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A Amendment No. 1 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A Amendment No. 1 (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-15324 STAR SCIENTIFIC |
|
| March 18, 2013 |
INFORMATION REGARDING SUBIDIARIES OF THE REGISTRANT Exhibit 21.1 INFORMATION REGARDING SUBIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Star Tobacco, Inc Virginia Rock Creek Pharmaceuticals, Inc. Delaware |
|
| March 18, 2013 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-15324 STAR SCIENTIFIC, INC. |
|
| March 18, 2013 |
EXHIBIT 10.83 AMENDMENT TO THE THIRD AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN STAR SCIENTIFIC, INC. AND PAUL L. PERITO This Amendment (“Amendment”) to that certain Third Amended and Restated Executive Employment Agreement between Star Scientific, Inc., a Delaware corporation (the “Company”) and Paul L. Perito (“Executive”) dated as of March 14, 2011 (the “Executive Employment Ag |
|
| March 18, 2013 |
EXHIBIT 10.84 AMENDMENT TO THE EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN STAR SCIENTIFIC, INC. AND JONNIE R. WILLIAMS, SR. This Amendment (“Amendment”) to that certain Executive Employment Agreement between Star Scientific, Inc., a Delaware corporation (the “Company”) and Jonnie R. Williams, Sr. (“Executive”) dated as of March 14, 2011 (the “Executive Employment Agreement”) is made as of this 28th da |
|
| January 22, 2013 |
RCPI / Rock Creek Pharmaceuticals, Inc. / McKeon John Joseph - SC 13G/A Passive Investment SC 13G/A 1 v332614sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) STAR SCIENTIFIC, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 85517P101 (CUSIP Number) December 31, 2012 (Date of Event which Requires filing of this Statement) Check the appropriate box to design |
|
| January 16, 2013 |
SC 13D/A 1 d469148dsc13da.htm AMENDMENT NO. 8 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Star Scientific, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 85517P 10 1 (CUSIP Number) Jay B. Gould, Esq. Pillsbury Winthrop Shaw Pittman LLP Four Embarcadero Center, Su |
|
| January 11, 2013 |
Star Scientific, Inc. 12,222,364 Shares of Common Stock 424B7 1 v331898424b7.htm 424B7 Prospectus Supplement to Prospectus dated April 29, 2011 Filed pursuant to Rule 424(b)(7) Registration No. 333-173627 Star Scientific, Inc. 12,222,364 Shares of Common Stock This prospectus supplement amends and supplements our prospectus dated April 29, 2011, or the Prospectus. The Prospectus relates to 12,222,364 shares of our common stock that may be offered for r |
|
| December 18, 2012 |
Exhibit 3.1 EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF STAR SCIENTIFIC, INC. (formerly Eye Technology, Inc.) The undersigned, a natural person, for the purpose of amending and restating, the Certificate of Incorporation of Star Scientific, Inc., as originally filed on June 24, 1985, and as amended and restated on June 22, 1988, May 19, 1992, September 24, 2001, December 14, 2007, |
|
| December 18, 2012 |
8-K 1 v3304978k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): 12/14/12 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorporati |
|
| December 17, 2012 |
Costs Associated with Exit or Disposal Activities 8-K 1 v3304198k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): 12/14/12 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorporati |
|
| November 30, 2012 |
RCPI / Rock Creek Pharmaceuticals, Inc. / McKeon John Joseph - SC 13G Passive Investment SC 13G 1 v329451sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) STAR SCIENTIFIC, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 85517P101 (CUSIP Number) November 28, 2012 (Date of Event which Requires filing of this Statement) Check the appropriate box to designate th |
|
| November 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| November 26, 2012 |
Amendment No. 7 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Star Scientific, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 85517P 10 1 (CUSIP Number) Jay B. Gould, Esq. Pillsbury Winthrop Shaw Pittman LLP Four Embarcadero Center, 22nd Floor San Francisco, CA 941 |
|
| November 16, 2012 |
8-K 1 v3287388k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): 11/15/12 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorporati |
|
| November 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| November 9, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15324 STAR SCIENTIFIC, INC. |
|
| November 2, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): 10/29/12 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 29, 2012 |
PRE 14A 1 v326883pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as pe |
|
| August 9, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15324 STAR SCIENTIFIC, INC. |
|
| June 29, 2012 |
Star Scientific, Inc. 10,835,254 Shares of Common Stock 424B3 1 v317355424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-182077 PROSPECTUS Star Scientific, Inc. 10,835,254 Shares of Common Stock This prospectus covers the offer and sale by the selling stockholders identified in this prospectus of up to 10,835,254 shares of common stock, $0.0001 par value per share, of Star Scientific, Inc., a Delaware corporation. Of this amount, 4, |
|
| June 25, 2012 |
CORRESP 1 filename1.htm June 25, 2012 VIA EDGAR CORRESPONDENCE The Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Karen Ubell Re: Star Scientific, Inc. Registration Statement on Form S-3 File No. 333-182077 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, Star Scien |
|
| June 22, 2012 |
S-3/A 1 v316654s3a.htm FORM S-3/A As filed with the Securities and Exchange Commission on June 22, 2012 Registration No. 333-182077 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Star Scientific, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 4470 Cox Road, Suite 110, |
|
| June 22, 2012 |
CORRESP 1 filename1.htm 555 Eleventh Street, N.W., Suite 1000 Washington, D.C. 20004-1304 Tel: +1.202.637.2200 Fax: +1.202.637.2201 www.lw.com FIRM / AFFILIATE OFFICES Abu Dhabi Moscow Barcelona Munich Beijing New Jersey Boston New York Brussels Orange County Chicago Paris Doha Riyadh Dubai Rome Frankfurt San Diego Hamburg San Francisco Hong Kong Shanghai Houston Silicon Valley London Singapore Lo |
|
| June 12, 2012 |
S-3 1 v315636s3.htm FORM S-3 As filed with the Securities and Exchange Commission on June 12, 2012 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Star Scientific, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 4470 Cox Road, Suite 110, Glen Allen, VA 23060 52-140213 |
|
| May 11, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): 5/10/12 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 11, 2012 |
Star Scientific Files First-Quarter Financials; Reports Continuing Increase in Anatabloc® Sales Exhibit 99.1 Star Scientific Files First-Quarter Financials; Reports Continuing Increase in Anatabloc® Sales GLEN ALLEN, Va., May 10, 2012 -Star Scientific, Inc., (NASDAQ: CIGX) today filed with the Securities Exchange Commission its Form 10-Q for the quarter ended March 31, 2012. The company reported net sales for the quarter ended March 31, 2012 of $1.2 million compared with $156 thousand for th |
|
| May 10, 2012 |
Exhibit 10.2 SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT Between STAR SCIENTIFIC, INC., as Issuer, And The Investor Set Forth on Schedule I hereto February 28, 2012 This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into and effective as of February 28, 2012, between Star Scientific, Inc., a Delaware corporation (the “Company”), and the investor set |
|
| May 10, 2012 |
Exhibit 10.1 SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT Between STAR SCIENTIFIC, INC., as Issuer, And The Investors Set Forth on Schedule I hereto February 28, 2012 This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into and effective as of February 28, 2012, between Star Scientific, Inc., a Delaware corporation (the “Company”), and the several inve |
|
| May 10, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-15324 STAR SCIENTIFIC, INC. |
|
| April 9, 2012 |
8-K 1 v3086698k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): 4/5/12 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorpor |
|
| March 15, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-15324 STAR SCIENTIFIC, INC. |
|
| March 15, 2012 |
EX-21.1 Exhibit 21.1 INFORMATION REGARDING SUBIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Star Tobacco, Inc Virginia Rock Creek Pharmaceuticals, Inc. Delaware |
|
| March 15, 2012 |
AMENDED AND RESTATED STAR SCIENTIFIC, INC. 2008 INCENTIVE AWARD PLAN ARTICLE 1. EXHIBIT 10.5 AMENDED AND RESTATED STAR SCIENTIFIC, INC. 2008 INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Star Scientific, Inc. 2008 Incentive Award Plan (the ?Plan?) is to promote the success and enhance the value of Star Scientific, Inc. (the ?Company?) by linking the personal interests of the members of the Board, Employees, and Consultants to those of the Company?s stockholders a |
|
| March 8, 2012 |
Regulation FD Disclosure - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): 3/7/12 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorporation) (Commission F |
|
| February 29, 2012 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities 8-K 1 d310076d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): 2/28/12 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorp |
|
| December 28, 2011 |
8-K 1 d273690d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): 12/22/11 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incor |
|
| December 28, 2011 |
Exhibit 10.1 Exhibit 10.1 SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT Between STAR SCIENTIFIC, INC., as Issuer, And The Investor Set Forth on Schedule I hereto December 22, 2011 This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into and effective as of December 22, 2011, between Star Scientific, Inc., a Delaware corporation (the “Company”), and the |
|
| December 23, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Star Scientific, Inc. (Name of issuer) Common Stock (Title of class of securities) 85517P101 (CUSIP number) Jonnie R. Williams Chief Executive Officer 4470 Cox Road Glen Allen, Virginia, 23060 (804) 527-1970 (Name, address and telephone number of person |
|
| December 20, 2011 |
EX-3.1 Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF STAR SCIENTIFIC, INC. (formerly Eye Technology, Inc.) The undersigned, a natural person, for the purpose of amending and restating, the Certificate of Incorporation of Star Scientific, Inc., as originally filed on June 24, 1985, and as amended and restated on June 22, 1988, May 19, 1992, September 24, 2001, December 14 |
|
| December 20, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): 12/16/11 STAR SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-15324 52-1402131 (State or other jurisdiction of incorporation) (Commission File Num |
